 | • レポートコード：MRC2-11QY03992 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、97ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は非アルコール性脂肪性肝疾患治療のグローバル市場について調査・分析したレポートです。種類別（酸化防止剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体作動薬、その他）市場規模、用途別（病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別非アルコール性脂肪性肝疾患治療の競争状況、市場シェア ・世界の非アルコール性脂肪性肝疾患治療市場：種類別市場規模 2015年-2020年（酸化防止剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体作動薬、その他） ・世界の非アルコール性脂肪性肝疾患治療市場：種類別市場規模予測 2021年-2026年（酸化防止剤、チアゾリジンジオン、ビグアニド、脂質低下剤、FXR受容体作動薬、その他） ・世界の非アルコール性脂肪性肝疾患治療市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他） ・世界の非アルコール性脂肪性肝疾患治療市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他） ・北米の非アルコール性脂肪性肝疾患治療市場分析：米国、カナダ ・ヨーロッパの非アルコール性脂肪性肝疾患治療市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの非アルコール性脂肪性肝疾患治療市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の非アルコール性脂肪性肝疾患治療市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの非アルコール性脂肪性肝疾患治療市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Roche、Daewoong、Cardax、Merck、Novartis、Gilead Sciences、AstraZeneca、Limerick BioPharma、GW Pharmaceuticals、Allergan、Takeda Pharmaceutical ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.
North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.
Market Analysis and Insights: Global Non Alcoholic Fatty Liver Disease Treatment Market
The global Non Alcoholic Fatty Liver Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Non Alcoholic Fatty Liver Disease Treatment Scope and Market Size
Non Alcoholic Fatty Liver Disease Treatment market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Non Alcoholic Fatty Liver Disease Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
GW Pharmaceuticals
Allergan
Takeda Pharmaceutical
Market segment by Type, the product can be split into
Antioxidants
Thiazolidinedione
Biguanides
Lipid lowering Agents
FXR Receptor Agonist
Others
Market segment by Application, split into
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Pharmacy
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non Alcoholic Fatty Liver Disease Treatment Revenue
1.4 Market by Type
1.4.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Antioxidants
1.4.3 Thiazolidinedione
1.4.4 Biguanides
1.4.5 Lipid lowering Agents
1.4.6 FXR Receptor Agonist
1.4.7 Others
1.5 Market by Application
1.5.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacy
1.5.3 Retail Pharmacy
1.5.4 Drug Stores
1.5.5 Online Pharmacy
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Perspective (2015-2026)
2.2 Global Non Alcoholic Fatty Liver Disease Treatment Growth Trends by Regions
2.2.1 Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non Alcoholic Fatty Liver Disease Treatment Historic Market Share by Regions (2015-2020)
2.2.3 Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non Alcoholic Fatty Liver Disease Treatment Market Growth Strategy
2.3.6 Primary Interviews with Key Non Alcoholic Fatty Liver Disease Treatment Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Market Size
3.1.1 Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Revenue (2015-2020)
3.1.2 Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Players (2015-2020)
3.1.3 Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Concentration Ratio
3.2.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2019
3.3 Non Alcoholic Fatty Liver Disease Treatment Key Players Head office and Area Served
3.4 Key Players Non Alcoholic Fatty Liver Disease Treatment Product Solution and Service
3.5 Date of Enter into Non Alcoholic Fatty Liver Disease Treatment Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Non Alcoholic Fatty Liver Disease Treatment Historic Market Size by Type (2015-2020)
4.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
5.2 Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Non Alcoholic Fatty Liver Disease Treatment Market Size (2015-2020)
6.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in North America (2019-2020)
6.3 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020)
6.4 North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
7 Europe
7.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size (2015-2020)
7.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Europe (2019-2020)
7.3 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020)
7.4 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
8 China
8.1 China Non Alcoholic Fatty Liver Disease Treatment Market Size (2015-2020)
8.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in China (2019-2020)
8.3 China Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020)
8.4 China Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
9 Japan
9.1 Japan Non Alcoholic Fatty Liver Disease Treatment Market Size (2015-2020)
9.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Japan (2019-2020)
9.3 Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020)
9.4 Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size (2015-2020)
10.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020)
10.4 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
11 India
11.1 India Non Alcoholic Fatty Liver Disease Treatment Market Size (2015-2020)
11.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in India (2019-2020)
11.3 India Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020)
11.4 India Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size (2015-2020)
12.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Central & South America (2019-2020)
12.3 Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020)
12.4 Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Non Alcoholic Fatty Liver Disease Treatment Introduction
13.1.4 Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Roche
13.2.1 Roche Company Details
13.2.2 Roche Business Overview
13.2.3 Roche Non Alcoholic Fatty Liver Disease Treatment Introduction
13.2.4 Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.2.5 Roche Recent Development
13.3 Daewoong
13.3.1 Daewoong Company Details
13.3.2 Daewoong Business Overview
13.3.3 Daewoong Non Alcoholic Fatty Liver Disease Treatment Introduction
13.3.4 Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.3.5 Daewoong Recent Development
13.4 Cardax
13.4.1 Cardax Company Details
13.4.2 Cardax Business Overview
13.4.3 Cardax Non Alcoholic Fatty Liver Disease Treatment Introduction
13.4.4 Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.4.5 Cardax Recent Development
13.5 Merck
13.5.1 Merck Company Details
13.5.2 Merck Business Overview
13.5.3 Merck Non Alcoholic Fatty Liver Disease Treatment Introduction
13.5.4 Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.5.5 Merck Recent Development
13.6 Novartis
13.6.1 Novartis Company Details
13.6.2 Novartis Business Overview
13.6.3 Novartis Non Alcoholic Fatty Liver Disease Treatment Introduction
13.6.4 Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.6.5 Novartis Recent Development
13.7 Gilead Sciences
13.7.1 Gilead Sciences Company Details
13.7.2 Gilead Sciences Business Overview
13.7.3 Gilead Sciences Non Alcoholic Fatty Liver Disease Treatment Introduction
13.7.4 Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.7.5 Gilead Sciences Recent Development
13.8 AstraZeneca
13.8.1 AstraZeneca Company Details
13.8.2 AstraZeneca Business Overview
13.8.3 AstraZeneca Non Alcoholic Fatty Liver Disease Treatment Introduction
13.8.4 AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.8.5 AstraZeneca Recent Development
13.9 Limerick BioPharma
13.9.1 Limerick BioPharma Company Details
13.9.2 Limerick BioPharma Business Overview
13.9.3 Limerick BioPharma Non Alcoholic Fatty Liver Disease Treatment Introduction
13.9.4 Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.9.5 Limerick BioPharma Recent Development
13.10 GW Pharmaceuticals
13.10.1 GW Pharmaceuticals Company Details
13.10.2 GW Pharmaceuticals Business Overview
13.10.3 GW Pharmaceuticals Non Alcoholic Fatty Liver Disease Treatment Introduction
13.10.4 GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
13.10.5 GW Pharmaceuticals Recent Development
13.11 Allergan
10.11.1 Allergan Company Details
10.11.2 Allergan Business Overview
10.11.3 Allergan Non Alcoholic Fatty Liver Disease Treatment Introduction
10.11.4 Allergan Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
10.11.5 Allergan Recent Development
13.12 Takeda Pharmaceutical
10.12.1 Takeda Pharmaceutical Company Details
10.12.2 Takeda Pharmaceutical Business Overview
10.12.3 Takeda Pharmaceutical Non Alcoholic Fatty Liver Disease Treatment Introduction
10.12.4 Takeda Pharmaceutical Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020)
10.12.5 Takeda Pharmaceutical Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Non Alcoholic Fatty Liver Disease Treatment Key Market Segments
Table 2. Key Players Covered: Ranking by Non Alcoholic Fatty Liver Disease Treatment Revenue
Table 3. Ranking of Global Top Non Alcoholic Fatty Liver Disease Treatment Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Antioxidants
Table 6. Key Players of Thiazolidinedione
Table 7. Key Players of Biguanides
Table 8. Key Players of Lipid lowering Agents
Table 9. Key Players of FXR Receptor Agonist
Table 10. Key Players of Others
Table 11. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions (2015-2020)
Table 15. Global Non Alcoholic Fatty Liver Disease Treatment Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Non Alcoholic Fatty Liver Disease Treatment Market Growth Strategy
Table 21. Main Points Interviewed from Key Non Alcoholic Fatty Liver Disease Treatment Players
Table 22. Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Players (2015-2020) (Million US$)
Table 23. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Players (2015-2020)
Table 24. Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non Alcoholic Fatty Liver Disease Treatment as of 2019)
Table 25. Global Non Alcoholic Fatty Liver Disease Treatment by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Non Alcoholic Fatty Liver Disease Treatment Product Solution and Service
Table 28. Date of Enter into Non Alcoholic Fatty Liver Disease Treatment Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 31. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Type (2015-2020)
Table 32. Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Type (2021-2026)
Table 33. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Application (2015-2020)
Table 34. Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 35. Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Application (2021-2026)
Table 36. North America Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2019-2020)
Table 38. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 39. North America Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2015-2020)
Table 40. North America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 41. North America Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2015-2020)
Table 42. Europe Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2019-2020)
Table 44. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2015-2020)
Table 46. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2015-2020)
Table 48. China Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2019-2020) (Million US$)
Table 49. China Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2019-2020)
Table 50. China Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 51. China Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2015-2020)
Table 52. China Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 53. China Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2015-2020)
Table 54. Japan Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2019-2020)
Table 56. Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2015-2020)
Table 58. Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2019-2020)
Table 62. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2015-2020)
Table 64. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2015-2020)
Table 66. India Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2019-2020) (Million US$)
Table 67. India Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2019-2020)
Table 68. India Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 69. India Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2015-2020)
Table 70. India Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 71. India Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2019-2020)
Table 74. Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2015-2020)
Table 76. Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2015-2020)
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer Product
Table 81. Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 82. Pfizer Recent Development
Table 83. Roche Company Details
Table 84. Roche Business Overview
Table 85. Roche Product
Table 86. Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 87. Roche Recent Development
Table 88. Daewoong Company Details
Table 89. Daewoong Business Overview
Table 90. Daewoong Product
Table 91. Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 92. Daewoong Recent Development
Table 93. Cardax Company Details
Table 94. Cardax Business Overview
Table 95. Cardax Product
Table 96. Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 97. Cardax Recent Development
Table 98. Merck Company Details
Table 99. Merck Business Overview
Table 100. Merck Product
Table 101. Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 102. Merck Recent Development
Table 103. Novartis Company Details
Table 104. Novartis Business Overview
Table 105. Novartis Product
Table 106. Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 107. Novartis Recent Development
Table 108. Gilead Sciences Company Details
Table 109. Gilead Sciences Business Overview
Table 110. Gilead Sciences Product
Table 111. Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 112. Gilead Sciences Recent Development
Table 113. AstraZeneca Business Overview
Table 114. AstraZeneca Product
Table 115. AstraZeneca Company Details
Table 116. AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 117. AstraZeneca Recent Development
Table 118. Limerick BioPharma Company Details
Table 119. Limerick BioPharma Business Overview
Table 120. Limerick BioPharma Product
Table 121. Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 122. Limerick BioPharma Recent Development
Table 123. GW Pharmaceuticals Company Details
Table 124. GW Pharmaceuticals Business Overview
Table 125. GW Pharmaceuticals Product
Table 126. GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 127. GW Pharmaceuticals Recent Development
Table 128. Allergan Company Details
Table 129. Allergan Business Overview
Table 130. Allergan Product
Table 131. Allergan Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 132. Allergan Recent Development
Table 133. Takeda Pharmaceutical Company Details
Table 134. Takeda Pharmaceutical Business Overview
Table 135. Takeda Pharmaceutical Product
Table 136. Takeda Pharmaceutical Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2015-2020) (Million US$)
Table 137. Takeda Pharmaceutical Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Type: 2020 VS 2026
Figure 2. Antioxidants Features
Figure 3. Thiazolidinedione Features
Figure 4. Biguanides Features
Figure 5. Lipid lowering Agents Features
Figure 6. FXR Receptor Agonist Features
Figure 7. Others Features
Figure 8. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Application: 2020 VS 2026
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Drug Stores Case Studies
Figure 12. Online Pharmacy Case Studies
Figure 13. Others Case Studies
Figure 14. Non Alcoholic Fatty Liver Disease Treatment Report Years Considered
Figure 15. Global Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions: 2020 VS 2026
Figure 17. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Players in 2019
Figure 20. Global Top Non Alcoholic Fatty Liver Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non Alcoholic Fatty Liver Disease Treatment as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Non Alcoholic Fatty Liver Disease Treatment Revenue in 2019
Figure 22. North America Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Bottom-up and Top-down Approaches for This Report
Figure 30. Data Triangulation
Figure 31. Key Executives Interviewed
非アルコール性脂肪肝疾患治療薬の世界市場（～2026年） Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …- 脂肪肝治療の世界市場（～2026年） Fatty liver disease is one of the most common liver dysfunction where the triglyceride fat accumulates in liver cells. The major risks associated with fatty liver disease are alcoholic cirrhosis, cardiovascular disorder, metabolic syndrome and biliary cirrhosis among others. Market Analysis and Insi…
- 肝疾患治療の世界市場（～2026年） Liver diseases are of different types such as hepatitis, liver cancer, non-alcoholic fatty liver disease, and liver cirrhosis. Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. Market Analysis and Insights: Global Liver Disease Treatment Market T…
- 遊離脂肪酸受容体4の世界市場（～2026年） Market Analysis and Insights: Global Free Fatty Acid Receptor 4 Market The global Free Fatty Acid Receptor 4 market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Free Fatty Acid Receptor 4 Scope and Market Size Free Fatty A…
- クラッベ病治療の世界市場（～2026年） Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…